SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 9119.
  • 2
    Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009; 43: 15768.
  • 3
    Rajala MW, Scherer PE. Minireview. The adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144: 376573.
  • 4
    Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 578995.
  • 5
    Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol 2010; 31: 22835.
  • 6
    Neumeier M, Weigert J, Schaffler A, Wehrwein G, Muller-Ladner U, Scholmerich J, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 2006; 79: 8038.
  • 7
    Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of NF-κB signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002; 277: 2935962.
  • 8
    Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 12939.
  • 9
    Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278: 508107.
  • 10
    Haugen F, Drevon CA. Activation of nuclear factor-κB by high molecular weight and globular adiponectin. Endocrinology 2007; 148: 547886.
  • 11
    Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94: e2731.
  • 12
    Liu Y, Michael MD, Kash S, Bensch WR, Monia BP, Murray SF, et al. Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 2007; 148: 68392.
  • 13
    Ajuwon KM, Banz W, Winters TA. Stimulation with peptidoglycan induces interleukin 6 and TLR2 expression and a concomitant downregulation of expression of adiponectin receptors 1 and 2 in 3T3-L1 adipocytes. J Inflamm (Lond) 2009; 6: 8.
  • 14
    Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006; 21: 164856.
  • 15
    Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331: 5206.
  • 16
    Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, et al. Adiponectin inhibits induction of TNF-α/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett 2008; 582: 4516.
  • 17
    Yamaguchi N, Kukita T, Li YJ, Martinez Argueta JG, Saito T, Hanazawa S, et al. Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol 2007; 49: 2834.
  • 18
    Turner JJ, Smolinska MJ, Sacre SM, Foxwell BM. Induction of TLR tolerance in human macrophages by adiponectin: does LPS play a role? Scand J Immunol 2009; 69: 32936.
  • 19
    Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the proinflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092101.
  • 20
    Caldefie-Chezet F, Poulin A, Tridon A, Sion B, Vasson MP. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 2001; 69: 4148.
  • 21
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 42630.
  • 22
    Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008; 3: e2267.
  • 23
    Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 174858.
  • 24
    Ognjanovic S, Ku TL, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. Am J Obstet Gynecol 2005; 193: 27382.
  • 25
    Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 322534.
  • 26
    Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol 2006; 176: 446878.
  • 27
    Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198201.
  • 28
    Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scholmerich J, et al. Adipocytokines in synovial fluid. JAMA 2003; 290: 170910.
  • 29
    Senolt L, Pavelka K, Housa D, Haluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006; 35: 24752.
  • 30
    Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K, et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 2009; 28: 44551.
  • 31
    Giles JT, Allison M, Bingham CO III, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009; 61: 124856.
  • 32
    Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jorgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol 2009; 36: 188591.
  • 33
    Choi HM, Lee YA, Lee SH, Hong SJ, Hahm DH, Choi SY, et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009; 11: R161.
  • 34
    Kitahara K, Kusunoki N, Kakiuchi T, Suguro T, Kawai S. Adiponectin stimulates IL-8 production by rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2009; 378: 21823.
  • 35
    Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-κB pathway. J Immunol 2007; 179: 548392.
  • 36
    Frommer KW, Zimmermann B, Meier FM, Schroder D, Heil M, Schaffler A, et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010; 62: 288699.
  • 37
    Ebina K, Oshima K, Matsuda M, Fukuhara A, Maeda K, Kihara S, et al. Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. Biochem Biophys Res Commun 2009; 378: 18691.
  • 38
    Lee SW, Kim JH, Park MC, Park YB, Lee SK. Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. Scand J Rheumatol 2008; 37: 2608.
  • 39
    Granado M, Martin AI, Castillero E, Lopez-Calderon A, Villanua MA. Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation. Eur J Pharmacol 2009; 608: 97103.
  • 40
    Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005; 29: 131520.
  • 41
    Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 698701.
  • 42
    Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 45863.
  • 43
    Forsblad d'Elia H, Pullerits R, Carlsten H, Bokarewa M. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 10827.
  • 44
    Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 9526.
  • 45
    Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 9701.
  • 46
    Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M. Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 1999; 48: 7458.
  • 47
    Hizmetli S, Kisa M, Gokalp N, Bakici MZ. Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int 2007; 27: 3358.
  • 48
    Palmer G, Gabay C. A role for leptin in rheumatic diseases? Ann Rheum Dis 2003; 62: 9135.
  • 49
    Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 11958.
  • 50
    Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M. Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 2006; 99: 107883.
  • 51
    Lee SW, Park MC, Park YB, Lee SK. Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int 2007; 27: 53740.
  • 52
    Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1205.
  • 53
    Busso N, So A, Chobaz-Peclat V, Morard C, Martinez-Soria E, Talabot-Ayer D, et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 2002; 168: 87582.
  • 54
    Bernotiene E, Palmer G, Talabot-Ayer D, Szalay-Quinodoz I, Aubert ML, Gabay C. Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice. Arthritis Res Ther 2004; 6: R25663.
  • 55
    Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gomez-Reino J, et al. Towards a proinflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006; 45: 94450.
  • 56
    Otero M, Lago R, Gomez R, Lago F, Gomez-Reino JJ, Gualillo O. Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect 2006; 19: 216.
  • 57
    Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295301.
  • 58
    Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, et al. Regulation of pre–B cell colony-enhancing factor by STAT-3–dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006; 54: 208495.
  • 59
    Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, et al. Pre–B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 282939.
  • 60
    Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 131827.
  • 61
    Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005; 68: 182533.
  • 62
    Rovin BH, Song H. Chemokine induction by the adipocyte-derived cytokine adiponectin. Clin Immunol 2006; 120: 99105.
  • 63
    Harle P, Pongratz G, Weidler C, Buttner R, Scholmerich J, Straub RH. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2004; 63: 80916.
  • 64
    Almehed K, d'Elia HF, Bokarewa M, Carlsten H. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: R15.
  • 65
    Filkova M, Liskova M, Hulejova H, Haluzik M, Gatterova J, Pavelkova A, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 2009; 68: 2956.
  • 66
    Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, Tahiri K, et al. Crucial role of visfatin/pre–B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 2008; 58: 1399409.
  • 67
    Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem 2008; 283: 3630010.
  • 68
    Toussirot E, Streit G, Nguyen NU, Dumoulin G, Le Huede G, Saas P, et al. Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007; 56: 13839.
  • 69
    Sari I, Demir T, Kozaci LD, Akar S, Kavak T, Birlik M, et al. Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 142732.
  • 70
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 16948.
  • 71
    Park MC, Lee SW, Choi ST, Park YB, Lee SK. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 2007; 36: 1016.
  • 72
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 73
    Park MC, Chung SJ, Park YB, Lee SK. Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine 2009; 76: 1705.
  • 74
    Kotulska A, Kucharz EJ, Brzezinska-Wcislo L, Wadas U. A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 2001; 20: 3002.
  • 75
    Kumpers P, Horn R, Brabant G, Woywodt A, Schiffer M, Haller H, et al. Serum leptin and ghrelin correlate with disease activity in ANCA-associated vasculitis. Rheumatology (Oxford) 2008; 47: 4847.
  • 76
    Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bulbul M, Ozerol E, et al. Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity. Br J Dermatol 2002; 147: 3316.
  • 77
    Yalcindag FN, Yalcindag A, Batioglu F, Caglayan O, Kisa U, Ozdemir O. Evaluation of serum resistin levels in patients with ocular and non-ocular Behcet's disease. Can J Ophthalmol 2008; 43: 4735.
  • 78
    Schaffler A, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, et al. Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes 2004; 112: 3839.
  • 79
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 267469.
  • 80
    Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 14317.
  • 81
    Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 2003; 300: 4726.
  • 82
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 30712.
  • 83
    Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68: 43746.
  • 84
    Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 316570.
  • 85
    Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304: 11548.
  • 86
    Garitaonandia I, Smith JL, Kupchak BR, Lyons TJ. Adiponectin identified as an agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal Transduct Res 2009; 29: 6773.
  • 87
    Gonez LJ, Naselli G, Banakh I, Niwa H, Harrison LC. Pancreatic expression and mitochondrial localization of the progestin-adipoQ receptor PAQR10. Mol Med 2008; 14: 697704.
  • 88
    Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006; 169: 204253.
  • 89
    Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 16775.
  • 90
    Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 9971001.
  • 91
    Remesar X, Rafecas I, Fernandez-Lopez JA, Alemany M. Leptin. Med Res Rev 1997; 17: 22534.
  • 92
    Clarke KJ, Zhong Q, Schwartz DD, Coleman ES, Kemppainen RJ, Judd RL. Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun 2003; 312: 9459.
  • 93
    Choi KC, Lee SY, Yoo HJ, Ryu OH, Lee KW, Kim SM, et al. Effect of PPAR-δ agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. Biochem Biophys Res Commun 2007; 357: 627.
  • 94
    Degawa-Yamauchi M, Moss KA, Bovenkerk JE, Shankar SS, Morrison CL, Lelliott CJ, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor α. Obes Res 2005; 13: 6629.
  • 95
    Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism. Biochem Biophys Res Commun 2006; 349: 87582.
  • 96
    Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277: 1975461.
  • 97
    Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 38590.
  • 98
    Serelis J, Kontogianni MD, Katsiougiannis S, Bletsa M, Tektonidou MG, Skopouli FN. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol 2008; 27: 7957.
  • 99
    Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 2009; 36: 72430.
  • 100
    Peters MJ, Watt P, Cherry L, Welsh P, Henninger E, Dijkmans BA, et al. Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann Rheum Dis 2010; 69: 168790.
  • 101
    Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, et al. Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 3116.